[{"id":"e8dda3b0-a18d-49f2-aff0-9fcff54c9572","acronym":"","url":"https://clinicaltrials.gov/study/NCT02561234","created_at":"2021-01-18T12:24:05.669Z","updated_at":"2024-07-02T16:36:21.118Z","phase":"Phase 1/2","brief_title":"A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02561234","lead_sponsor":"Aeglea Biotherapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loargys (pegzilarginase)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2021-11-05"},{"id":"34ff7b66-559e-4e32-a51e-853b748d52dc","acronym":"PACOX","url":"https://clinicaltrials.gov/study/NCT02089633","created_at":"2021-01-18T09:38:26.218Z","updated_at":"2024-07-02T16:37:19.417Z","phase":"Phase 2","brief_title":"Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC","source_id_and_acronym":"NCT02089633 - PACOX","lead_sponsor":"Bio-Cancer Treatment International Limited","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • pegylated recombinant human arginase (BCT-100)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2017-07-28"}]